Barclays PLC Acer Therapeutics Inc. Transaction History

Barclays PLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$2.52 - $3.18 $19,497 - $24,603	-7,737 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$2.47 - $4.39 $116,880 - $207,734	-47,320 Reduced 85.95%	7,737 $24,000
Q4 2020 Feb 11, 2021	SELL	$2.34 - $2.99 $1,275 - $1,629	-545 Reduced 0.98%	55,057 $144,000
Q3 2020 Nov 12, 2020	SELL	$2.16 - $5.41 $84,177 - $210,833	-38,971 Reduced 41.21%	55,602 $160,000
Q2 2020 Aug 12, 2020	SELL	$1.53 - $4.53 $347 - $1,028	-227 Reduced 0.24%	94,573 $324,000
Q1 2020 May 13, 2020	SELL	$1.18 - $5.86 $3,960 - $19,666	-3,356 Reduced 3.42%	94,800 $188,000
Q4 2019 Feb 10, 2020	BUY	$2.85 - $4.2 $7,130 - $10,508	2,502 Added 2.62%	98,156 $393,000
Q3 2019 Nov 14, 2019	BUY	$1.95 - $3.93 $95,594 - $192,660	49,023 Added 105.13%	95,654 $305,000
Q2 2019 Aug 14, 2019	BUY	$3.45 - $26.86 $7,365 - $57,346	2,135 Added 4.8%	46,631 $182,000
Q1 2019 May 15, 2019	BUY	$20.4 - $25.15 $401,798 - $495,354	19,696 Added 79.42%	44,496 $1.08 Million
Q4 2018 Feb 14, 2019	BUY	$16.55 - $30.22 $410,440 - $749,456	24,800 New	24,800 $499,000

365

Ticker ACER
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,100,000
Description
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mu...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.